Table 4.
Patient‐reported burden in the Cyclo and IMM populations
| Outcome | Cyclo | Severe excluding Cyclo | IMM | Severe excluding IMM |
|---|---|---|---|---|
| Itch, n | 62 | 355 | 102 | 336 |
| NRS, mean (SD) | 6.6 (2.2) | 7.0 (2.2) | 6.5 (2.3)* | 7.0 (2.2) |
| PO‐SCORAD VAS, mean (SD) | 7.0 (2.2) | 7.2 (2.1) | 6.9 (2.3) | 7.2 (2.1) |
| Pain NRS, mean (SD) | 4.6 (2.5) | 4.5 (2.7) | 4.7 (2.7) | 4.4 (2.7) |
| Sleep | ||||
| PO‐SCORAD VAS, mean (SD) [n] | 5.0 (2.9) [62] | 5.5 (2.8) [355] | 4.9 (2.9) [102] | 5.5 (2.8) [336] |
| Sleep disturbed every night over past week (POEM item 2), n (%) | 15 (24.2) | 94 (26.5) | 25 (24.5) | 88 (26.2) |
| Sleep disturbance frequency (POEM item 2), n (%) | ||||
| No nights | 6 (9.7) | 32 (9.0) | 10 (9.8) | 30 (8.9) |
| 1–2 nights | 10 (16.1) | 83 (23.4) | 25 (24.5) | 79 (23.5) |
| 3–4 nights | 20 (32.3) | 95 (26.8) | 28 (27.5) | 89 (26.5) |
| 5–6 nights | 10 (16.1) | 49 (13.8) | 12 (11.8) | 48 (14.3) |
| Every night | 15 (24.2) | 94 (26.5) | 25 (24.5) | 88 (26.2) |
| Hours of sleep per night over the past week, mean (SD) [n] | 6.0 (1.5) [60] | 5.6 (1.6) [347] | 5.9 (1.4) [99] | 5.6 (1.6) [328] |
| HADS, n | 62 | 355 | 102 | 336 |
| Total score, mean (SD) | 17.0 (8.1)† | 17.5 (7.8) | 16.6 (8.1)ߥ | 17.3 (7.8) |
| HADS‐A score, mean (SD) | 9.2 (4.2)† | 9.3 (4.1) | 9.1 (4.2)ߥ | 9.3 (4.1) |
| HADS‐D score, mean (SD) | 7.8 (4.6)† | 8.1 (4.3) | 7.5 (4.6)ߥ | 8.1 (4.3) |
| HADS‐A ≥8, n (%) | 41 (66.1) | 229 (64.5) | 67 (65.7) | 214 (63.7) |
| HADS‐A ≥11, n (%) | 21 (33.9) | 140 (39.4) | 35 (34.3) | 132 (39.3) |
| HADS‐D ≥8, n (%) | 31 (50.0) | 199 (56.1) | 51 (50.0) | 187 (55.7) |
| HADS‐D ≥11, n (%) | 18 (29.0) | 104 (29.3) | 29 (28.4) | 95 (28.3) |
| DLQI, n | 59 | 350 | 98 | 331 |
| Total score, mean (SD) | 15.2 (6.8) | 16.0 (6.9) | 14.9 (6.9) | 16.0 (6.9) |
| Symptoms and feelings, mean (SD) | 4.0 (1.4) | 4.3 (1.3) | 4.0 (1.5) | 4.2 (1.3) |
| Daily activities, mean (SD) | 3.2 (1.7) | 3.4 (1.6) | 3.1 (1.7) | 3.4 (1.7) |
| Leisure, mean (SD) | 2.9 (1.8) | 3.1 (1.9) | 2.7 (1.9) | 3.1 (1.9) |
| Work and school, mean (SD) | 1.5 (1.2) | 1.5 (1.2) | 1.4 (1.2) | 1.5 (1.2) |
| Personal relationships, mean (SD) | 2.2 (1.7) | 2.4 (1.9) | 2.2 (1.8) | 2.4 (1.9) |
| Treatment, mean (SD) | 1.5 (0.8) | 1.4 (1.0) | 1.5 (0.9) | 1.4 (0.9) |
| Productivity in past 4 weeks among part‐/full‐time employees or students, n | 47 | 294 | 75 | 282 |
| At least 1 day missed, n (%) | 34 (72.3) | 183 (62.2) | 51 (68.0) | 175 (62.1) |
| Total number of days missed related to atopic dermatitis, mean (SD) [n] | 3.8 (5.8) [44] | 3.7 (5.8) [283] | 3.2 (4.9) [71] | 3.7 (5.9) [271] |
*P < 0.05 vs. for IMM vs. severe group excluding IMM participants.
†n = 61. ߥn = 101.
DLQI, Dermatology Quality of Life Index; HADS, Hospital Anxiety and Depression Scale; HADS‐A, HADS anxiety subscale; HADS‐D, HADS depression subscale; NRS, numerical rating scale; POEM, Patient‐Oriented Eczema Measure; PO‐SCORAD, Patient‐Oriented Scoring of Atopic Dermatitis; SD, standard deviation; VAS, visual analogue scale.